Abstracts tagged "interstitial lung disease and prognostic factors"

Abstract Number: 2844 • 2019 ACR/ARP Annual Meeting
Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease
Takahisa Gono¹, Kenichi Masui ², Naoshi Nishina ³, Shinji Sato ⁴ and Masataka Kuwana ⁵, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ²Department of Anaesthesiology, Show University School of Medicine, Saitama, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is useful to predict mortality in patients with myositis–associated interstitial lung disease (ILD) because of high prevalence of…
Abstract Number: 1566 • 2018 ACR/ARHP Annual Meeting
Prevalence and Prognosis of Interstitial Lung Disease in a Large Cohort of Chinese Primary Sjögren’s Syndrome Patients
Hui Gao^1,2, Xuewu Zhang¹, Jing He³, Jing Zhang⁴, Ye Sun⁵ and Zhan-Guo Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China, ³Rheumatology, Peking University People's Hospital, Beijing, China, ⁴Peking University International Hospital, Beijing, China, ⁵Department of Radiology, Peking University People's Hospital, Beijing, China
Background/Purpose: To determine the prevalence and identify the prognosis associated with pulmonary involvement in pSS patients. Methods: A total of 1341 hospitalized patients (853 with…
Abstract Number: 2167 • 2018 ACR/ARHP Annual Meeting
Incidence and Baseline Characteristics of Exacerbation in Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-Scale Cross-Sectional Cohort Study
Okinori Murata, Nobuhito Sasaki and Makoto Maemondo, Division of Pulmonary medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
Background/Purpose: Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been…
Abstract Number: 2328 • 2016 ACR/ARHP Annual Meeting
Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis
Kazuhiro Kurasawa¹, Satoko Arai¹, Yumeko Namiki¹, Ayae Tanaka¹, Ryutaro Yamazaki², Harutsugu Okada¹, Takayoshi Owada¹, Masafumi Arima¹ and Reika Maezawa¹, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan
Background/Purpose: Anti-MDA5 Ab positive dermatomyositis (DM) is a unique subset of inflammatory myopathy characterized by non- or mild muscle weakness, skin manifestation such as…
Abstract Number: 2907 • 2016 ACR/ARHP Annual Meeting
Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)
Lise Moreer¹, Hilario Nunes¹, Louise Bondeelle¹, Yurdagul Uzunhan¹, Pascale Ghillani-Dalbin², Dominique Valeyre¹, Lucile Musset³ and Makoto Miyara³, ¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
Background/Purpose: ILD is a frequent and potentially severe complication of CTDs. The course of ILD can be difficult to predict in this setting. The term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].